Emisphere Technologies, Inc. and Syracuse University Enter Research Agreement to Test Oral Drug Delivery Systems

CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS.OB) and Syracuse University have entered into a research agreement to combine Emisphere’s proprietary Eligen® oral drug delivery technology with a new oral drug delivery system developed in the laboratory of Robert Doyle, Assistant Professor of Chemistry in Syracuse University’s College of Arts and Sciences. The experiments will test whether the combination of Eligen® and Doyle’s oral drug delivery technology will enhance the absorption of an appetite-suppressing hormone.